Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CY6463 in stable schizophrenia
NCT04972227Phase 1Completed
- Sponsor
- Tisento Therapeutics
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing CY6463 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to study drug discontinuation at 28 days. Started Sep 2021; status: completed.
02
Drugs
zagociguat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04972227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972227.